Building on the extraordinary success of its platform in producing an effective coronavirus vaccine, German mRNA specialist BioNTech (Nasdaq: BNTX) is making inroads on a project which broadens its focus to include checkpoint inhibition.
Data presented at the annual meeting of the American Society of Clinical Oncology (ASCO) demonstrate encouraging progress for its anti-CTLA-4 antibody gotistobart.
The company generated tens of billions of dollars with its vaccine Comirnaty sales, partnered with Pfizer (NYSE: PFE) - money that is now being put to good use.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze